MR-US Image Fusion Targeted Biopsy for Single-cell Prostate Cancer Research
Launched by YALE UNIVERSITY · Dec 9, 2014
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new method to better understand prostate cancer by looking closely at small samples of tissue taken from the prostate. Researchers believe that by analyzing these tiny samples at a single-cell level, they can gather important information about the cancer's characteristics. This could help doctors make more accurate predictions about how the cancer might progress, which is vital for guiding treatment decisions.
To take part in this study, participants need to be male adults aged 65 to 74 who are scheduled for a specific type of prostate biopsy called an Artemis biopsy. Unfortunately, individuals who cannot provide informed consent, meaning they can’t understand and agree to the study’s terms, will not be eligible. If you join the study, you can expect to provide a tissue sample during your biopsy, which will then be studied to improve our understanding of prostate cancer and potentially lead to better treatment approaches in the future.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Only subjects that have scheduled Artemis prostate biopsy with defined regions of interest will be included in this study
- Exclusion Criteria:
- • Any subjects that are unable to provide informed consent will be excluded
About Yale University
Yale University, a prestigious Ivy League institution located in New Haven, Connecticut, is renowned for its commitment to advancing medical research and clinical innovation. With a rich history of academic excellence and a robust infrastructure for scientific inquiry, Yale serves as a leading sponsor for clinical trials aimed at improving patient care and developing new therapeutic approaches. The university's multidisciplinary teams of researchers and clinicians collaborate to conduct rigorous and ethical studies, leveraging cutting-edge technologies and methodologies to address critical health challenges. Through its dedication to fostering an environment of inquiry and discovery, Yale University plays a pivotal role in translating research findings into clinical practice, ultimately enhancing health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Haven, Connecticut, United States
New Haven, Connecticut, United States
Patients applied
Trial Officials
Preston C Sprenkle, MD
Principal Investigator
Yale University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials